This article summarizes the diagnosis and treatment of a patient with late-stage lung adenocarcinoma with Her-2 overexpression and EGFR mutation, aiming to explore the treatment efficacy of the antibody-drug conjugate (ADC) disitamab vedotin. Here, ERBB2 is linked to lung adenocarcinoma.